Skip Nav Destination
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Ex vivo fucosylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo
Issue Archive
February 26 2015
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
PLENARY PAPER
MYELOID NEOPLASIA
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley,Brenton G. Mar,Emanuele Mazzola,Peter V. Grauman,Sarah Shareef,Steven L. Allen,Arnaud Pigneux,Meir Wetzler,Robert K. Stuart,Harry P. Erba,Lloyd E. Damon,Bayard L. Powell,Neal Lindeman,David P. Steensma,Martha Wadleigh,Daniel J. DeAngelo,Donna Neuberg,Richard M. Stone,Benjamin L. Ebert
PERSPECTIVES
BLOOD SPOTLIGHT
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Clinical Trials & Observations
Eric D. Jacobsen,Jeff P. Sharman,Yasuhiro Oki,Ranjana H. Advani,Jane N. Winter,Celeste M. Bello,Gary Spitzer,Maria Corinna Palanca-Wessels,Dana A. Kennedy,Pamela Levine,Jing Yang,Nancy L. Bartlett
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Clinical Trials & Observations
Antonio Omuro,Denise D. Correa,Lisa M. DeAngelis,Craig H. Moskowitz,Matthew J. Matasar,Thomas J. Kaley,Igor T. Gavrilovic,Craig Nolan,Elena Pentsova,Christian C. Grommes,Katherine S. Panageas,Raymond E. Baser,Geraldine Faivre,Lauren E. Abrey,Craig S. Sauter
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Clinical Trials & Observations
Xavier Leleu,Lionel Karlin,Margaret Macro,Cyrille Hulin,Laurent Garderet,Murielle Roussel,Bertrand Arnulf,Brigitte Pegourie,Brigitte Kolb,Anne Marie Stoppa,Sabine Brechiniac,Gerald Marit,Beatrice Thielemans,Brigitte Onraed,Claire Mathiot,Anne Banos,Laurence Lacotte,Mourad Tiab,Mamoun Dib,Jean-Gabriel Fuzibet,Marie Odile Petillon,Philippe Rodon,Marc Wetterwald,Bruno Royer,Laurence Legros,Lotfi Benboubker,Olivier Decaux,Martine Escoffre-Barbe,Denis Caillot,Jean Paul Fermand,Philippe Moreau,Michel Attal,Herve Avet-Loiseau,Thierry Facon,for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM),for the Intergroupe Francophone du Myélome (IFM)
HEMATOPOIESIS AND STEM CELLS
Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium
Il Ho Jang,Yi-Fen Lu,Long Zhao,Pamela L. Wenzel,Tsutomu Kume,Sumon M. Datta,Natasha Arora,Jordi Guiu,Mounia Lagha,Peter G. Kim,Eun Kyoung Do,Jae Ho Kim,Thorsten M. Schlaeger,Leonard I. Zon,Anna Bigas,Caroline E. Burns,George Q. Daley
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Ex vivo fucosylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo
Brief Report
Simrit Parmar,Xiaoying Liu,Amer Najjar,Nina Shah,Hong Yang,Eric Yvon,Katy Rezvani,Ian McNiece,Patrick Zweidler-McKay,Leonard Miller,Steve Wolpe,Bruce R. Blazar,Elizabeth J. Shpall
BLOOD WORK
-
Cover Image
Cover Image
![issue cover]()
Smooth muscle cells produce a pathological hyaluronan matrix (green) typified by cable-like structures when activated with the viral mimetic polyI:C or a number of other agents. Platelets (immunohistochemically stained red for CD42b) have the ability to bind to hyaluronan cables. Additionally, they carry the hyaluronan-degrading enzyme HYAL2 in their α granules. Upon activation, platelets rapidly transpose the enzyme to their surface, thus putting enzyme and substrate in close proximity. This results in hyaluronan matrix degradation. In this experiment, hyaluronan removal is blocked with any antibody to HYAL2. See the article by Albeiroti et al on page 1460.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
